Form 4: Elanco Animal Health Director Acquires Shares Through Deferred Stock Units

Craig S. Wallace, a director at Elanco Animal Health, acquired 13,838 shares of common stock through a grant of deferred stock units.

Summary

• Craig S. Wallace, a director of Elanco Animal Health, received 13,838 shares of common stock.
• The shares were acquired through a grant of deferred stock units as part of an annual equity award.
• The transaction occurred on November 29, 2024.
• The price per share for the acquisition was $0, as it was a grant of deferred stock units.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of equity compensation for a director, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The acquisition of shares by a director demonstrates confidence in the company's future.
• The grant of deferred stock units aligns the director's interests with those of the shareholders.

Industry Context

This is a standard practice for companies to provide equity compensation to board members to align their interests with the company's performance and shareholder value.

Comparison to Industry Standards

• Granting deferred stock units to non-employee directors is a common practice among publicly traded companies, including those in the animal health sector.
• Companies like Zoetis and IDEXX Laboratories also use equity-based compensation for their board members.
• The number of shares granted is typical for annual equity awards, though the specific amount varies based on company size and board compensation policies.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

Elanco Animal Health, Director, Craig S. Wallace, Deferred Stock Units, Equity Award, Share Acquisition, Form 4